H&H Group delivers income development throughout all three enterprise segments for 2022 and expects optimistic outlook for 2023

• Reported income development of 10.6% with income of RMB12,775.9 million and adjusted EBITDA development of 6.5% regardless of important headwinds
• Child Vitamin and Care phase returned to development (+1.1% on a like-for-like foundation), turnaround of the probiotics enterprise and stabilising the toddler milk system (IMF) enterprise in mainland China
• Grownup Vitamin and Care phase achieved strong development of 12.5%, with Swisse persevering with to be the no.1 participant in mainland China’s on-line VHMS market and growing market share within the Australia and New Zealand (ANZ) market in 2022
• Pet Vitamin and Care phase noticed 20.9%[1] total development, led by North America which is now our third-largest market and a serious supply of development
• 98.5% of adjusted EBITDA was transformed into working money stream, due to the Group’s excessive money era enterprise mannequin which can assist to deleverage the stability sheet whereas persevering with to drive development throughout the enterprise
• Maintained secure annual dividend pay-out ratio of fifty% to reward shareholders
• Important strides in sustainability progress together with sustaining Morgan Stanley Capital Worldwide (MSCI) ESG ranking of ‘A’ and Hong Kong High quality Assurance Company (HKQAA) ranking of ‘A’ for ESG efficiency

Main international household vitamin firm Well being and Happiness (H&H) Worldwide Holdings Restricted (inventory code: 1112.HK) has introduced its 2022 annual outcomes, delivering uninterrupted top-line development and like-for-like (LFL) enlargement, and reaching optimistic EBITDA throughout all three enterprise segments: Child Vitamin and Care (BNC), Grownup Vitamin and Care (ANC), and Pet Vitamin and Care (PNC).

Akash Bedi, Interim Chief Govt Officer and Chief Technique & Operations Officer, says, “I’m happy to announce that in 2022, because of our adaptable and agile enterprise construction and well-implemented methods, the Group demonstrated resilience and achieved robust outcomes. We made important progress in delivering worthwhile development by our long-term technique, which focuses on successful in core, globalisation and diversification, and investing in future development alternatives. Our final imaginative and prescient is to change into a worldwide chief in household vitamin and wellness, providing superior merchandise and aspirational manufacturers.”

Mr Bedi continued, “In 2022, the Group gained new shoppers throughout our key markets, in addition to increasing into new markets, whereas persevering with to drive model development by consumer-led innovation. We additionally accelerated our sustainability efforts, aiming to ship long-term enterprise development with a optimistic impression on our staff members, stakeholders, communities, and the setting. This cultivates an impact-driven mindset and reinforces our goal as a accountable and purpose-led organisation.”

Mainland China
Mainland China accounted for 74.9% of the Group’s whole income in 2022, reaching development of 6.4% on a LFL foundation. Biostime’s branded probiotics additionally noticed spectacular income development of 12.8% in comparison with 2021, solidifying its place because the no. 1 model within the mainland China probiotics market[2]. Our super-premium Biostime IMF phase additionally had a promising yr, with a market share of 12.1% and optimistic retail scan gross sales development, outperforming the general market development charge.

Mr Bedi feedback, “I’m happy that regardless of market challenges resulting from declining start charges and constrained demand, our IMF enterprise in mainland China has stabilised and we efficiently circled our probiotics enterprise, whereas remaining the no.1 model of youngsters’s probiotics worldwide.”

Mr Bedi cites consumer-led innovation and engagement as taking part in key roles in Biostime’s success in 2022.

“We launched next-generation new merchandise with a concentrate on participating our shoppers similar to Biostime Kids’s Milk Powder and probiotics containing lactoferrin – an important element of the human immune system. As well as, Biostime has launched ground-breaking analysis on goat milk LPN, which demonstrates the revolutionary and breakthrough outcomes of Biostime’s goat milk powder when it comes to key immune-boosting elements.”

The ANC phase skilled income development of 14.1%, accounting for 64.4% of the whole ANC income. Swisse ranked because the primary model within the Vitamin, Herb, and Mineral Complement (VHMS) on-line market in mainland China, with a market share of seven.5% (up from 6.6% in 2021), pushed by its new model positioning and introduction of revolutionary merchandise. Swisse’s model picture was revamped to ‘Swisse, Pure and Wholesome, Our New Style’, whereas the launch of the Swisse Plus premium vary catered to the wants of high-end Chinese language shoppers, that includes superior NAD+ merchandise and ldl cholesterol safety dietary supplements.

In 2022, the PNC phase made important progress in mainland China, with Strong Gold already rating because the quantity two model within the premium dry cat meals class, holding a 14.7% market share, regardless of its current entry into the market. Strong Gold centered on refreshing its model picture and launched new merchandise within the Chinese language market, increasing its presence to roughly 7,600 pet shops and pet hospitals offline. In December 2022, Zesty Paws was launched in mainland China by cross-border e-commerce.

Australia & New Zealand (ANZ)
Within the ANZ market, the ANC phase maintained double-digit income development (+11.7% on a LFL foundation) with promising income development in all channels and an total market share of 12.3%[3]. Swisse outpaced development within the home market with retail scan gross sales development of 12.9% vs 7.4% trade development within the twelve months ended 31 December 2022.

Mr Bedi feedback, “The expansion was fuelled by growing demand for immune and wellness merchandise, together with new merchandise led by the launch of the extremely acclaimed Swisse Collagen + Hyaluronic Acid Booster, which has rapidly change into the no.1 magnificence innovation out there.”

“We additionally noticed success with Biostime in ANZ in 2022 with the launch of Biostime ready-to-feed (RTF). As well as, we’re proud that our Australian Biostime Human Milk Oligosaccharides (HMOs) product vary gained the NutraIngredients Asia 2022 Editors Award for finest toddler and youngster vitamin initiative.”

North America
“After finishing the acquisition of Zesty Paws in 2021, our focus in 2022 was on integrating the model and our PNC phase additional into our enterprise. Consequently, North America has change into a major supply of development for our Group and is now our third largest market, largely as a result of success of our PNC phase,” provides Mr Bedi.
In 2022, Strong Gold and Zesty Paws achieved a reported income development of 152.5% in North America. Whole income for North America additionally elevated by 18.9% on a like-for-like foundation.

Zesty Paws stays the no.1 pet complement model in the US within the e-commerce channel with 11.5%[4] market share. Zesty Paws and Strong Gold continued to increase their distribution attain throughout the market together with into main chains similar to Walmart, Goal, PetSmart in addition to impartial pet shops, and at the moment are current in additional than 7,700 and three,400 shops, respectively.

Innovation was a core focus with the launch of the premium Strong Gold NutrientBoost vary and purposeful treats and toppers and new Zesty Paws Vet Power, Dental Bones and Pet merchandise.

Different Territories
Income from different territories was down 6.9% on a LFL foundation, accounting for 4.6% of the Group’s whole income. This was primarily resulting from strategic restructuring within the European markets placing stress on gross sales.

In Asia (excluding mainland China), the Group grew 39.0% on a LFL foundation with phenomenal development momentum in enlargement markets together with Vietnam, Thailand, India and Malaysia, pushed by distribution features (each in on-line and offline channels). Hong Kong SAR and Singapore reached robust home VHMS market share and contributed positively to development with EBITDA margins on par with the general ANC phase. Swisse additionally reached no.1 Magnificence from inside model in Singapore.

Mr Bedi says, “In Europe, we’re very proud that we maintained management within the French market, whereas specializing in enhancing model consciousness and celebrating new product launches. Biostime bolstered its no.1 place in each natural IMF in French pharmacy with 41.7%[5] market share and in Goat IMF with 41.5%[6] market share. In Italy, we’re happy to see that Swisse is now ranked no.2 within the Magnificence VHMS market with 9.3%[7] market share.”

Sustainability Progress
Mr Bedi says the Group is dedicated to driving enterprise efficiency whereas making a optimistic impression on its staff members, stakeholders, communities, and the planet.

“In 2022, we made important progress in our sustainability initiatives, reaching our sustainability objectives and driving shared worth by our 4 core impression areas. This consists of ‘Advancing the Story for Good Well being,’ ‘Decreasing our Footprint on the Planet,’ ‘Honouring Human Rights and Equity,’ and ‘Supporting Good Governance.’ We additionally maintained our ‘A’ ranking for ESG efficiency from MSCI and the HKQAA.”

In 2022, the H&H Board established an ESG Committee to refine its governance framework and oversee ESG dangers and alternatives.

H&H has made important progress in the direction of its sustainability objectives in 2022. The corporate accomplished a Group-wide carbon footprint evaluation for Scopes 1, 2, and three and developed science-based greenhouse fuel emissions discount targets, to be submitted to the Science Based mostly Targets initiative (SBTi). The Group additionally lowered water consumption depth in owned manufacturing amenities by 18.9% per unit produced, demonstrating its continued efforts to preserve pure sources. Embedding circularity into its merchandise and enterprise fashions has additionally been a key focus, with 98% of its packaging now being recyclable, biodegradable, or compostable. Examples of innovation on this space embrace the Swisse Earth vary in Australia, which makes use of award-winning packaging produced from as much as 70% recycled content material, and initiatives to cut back using virgin packaging, similar to decreasing the dimensions of vials for sure Swisse merchandise.

2023 Outlook
Waiting for 2023, Mr Bedi feedback that the Group stays optimistic because it strives for development, international enlargement, and diversification.

“Certainly one of our fundamental priorities might be to pursue natural development methods in each established and new markets, while additionally emphasising the significance of “successful in core” to drive profitability and development. We anticipate continued development in mainland China, with quicker enlargement in North America and different Asian markets with optimistic EBITDA. Moreover, we’ll concentrate on decreasing debt ranges and deleveraging its stability sheet to attain a more healthy monetary standing.”

The Group will prioritise the stabilisation of its IMF enterprise by specializing in development within the super-premium class, gaining market share in mainland China, and strengthening its place as the highest probiotics market share holder for each present and new merchandise. In February 2023, the Group obtained approval for the brand new ‘GB requirements’ for the Biostime Alpha Star IMF collection and stays assured concerning the approval of different collection whereas having deliberate our stock based mostly on the estimated approval timing and buyer demand.

The first focus for the ANC phase in mainland China might be to retain its main place, whereas growing its market share in cross-border e-commerce. Together with this, the Group will intention for double-digit development within the regular commerce market, constructing on its present no.4 rating with 2.0%[8] market share. Moreover, the phase goals to raise Swisse’s product portfolio by increasing into new product ranges like Swisse Plus. The precedence within the ANZ market might be to realize market share and regain its home management place, whereas Asia and Europe will focus on driving increased development and enhancing profitability.

For PNC in mainland China, the Group’s fundamental goal is to extend market share for Strong Gold within the premium cat meals class. In North America, the Group goals to increase Zesty Paws’ on-line management on Amazon and Chewy whereas selectively rising in offline channels to extend class penetration. The Group additionally plans to attain worthwhile development for Strong Gold by specializing in the super-premium class and increasing throughout e-commerce.

The Group will proceed to combine sustainability into its core technique and company governance, collaborating with the ESG Committee to establish important long-term sustainability tendencies that can form the longer term and impression the enterprise, thus enabling sustainable and long-term development.

The 2022 Annual Outcomes announcement is on the market right here.

[1] The LFL change of PNC phase and North America are on professional forma foundation as if the income of Zesty Paws for the twelve months ended 31 December 2022 and 2021 had been consolidated
[2] Kantar Shopper Panel, LTM 31 December 2022
[3] Market share knowledge from IQVIA, LTM 31 December 2022
[4] Stackline, YTD 31 December 2022
[5] GERS, LTM 31 December 2022
[6] IQVIA, LTM 31 December 2022
[7] IQVIA, LTM 31 December 2022
[8] Early Knowledge, LTM 31 December 2022

For media inquiries, contact:

H&H Group
Annabel Jenkins
+44 7514535600
[email protected]

Suppose Alliance Group
Matthew Schultz
+852 3481 1161
[email protected]